Biotech · Private company · Minneapolis, MN, US
Luminary Therapeutics
Track this companyFree. Adds Luminary Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials53 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Autologous CAR-T cell therapy expressing the BAFF-ligand.Phase 1 · Multiple Myeloma, RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- BAFF CAR-TPhase 1 · Lymphoma, Non-Hodgkin Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- LMY-920Phase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- LMY-922Phase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- LMY-922Phase 1 · Rheumatoid Arthritis (RA)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune DiseasePHASE1 · NOT_YET_RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07729995 · fetched Nov 12, 2026
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic MalignanciesPHASE1 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07679919 · fetched Nov 12, 2026
- BAFF CAR-T Cells (LMY-920) for Systemic Lupus ErythematosusPHASE1 · RECRUITING · started Apr 1, 2025ClinicalTrials.gov NCT06340750 · fetched Nov 12, 2026
- LMY-920 for Treatment of Relapsed or Refractory MyelomaPHASE1 · UNKNOWN · started Mar 13, 2024ClinicalTrials.gov NCT05546723 · fetched Nov 12, 2026
- Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin LymphomaPHASE1 · UNKNOWN · started Nov 21, 2023ClinicalTrials.gov NCT05312801 · fetched Nov 12, 2026
NIH awards3
- Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell MalignanciesFiscal year 2026 · $586.8KNIH RePORTER 5R44CA278021-03 · fetched Nov 12, 2026
- Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell MalignanciesFiscal year 2025 · $1.5MNIH RePORTER 4R44CA278021-02 · fetched Nov 12, 2026
- An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian CarcinomaFiscal year 2024 · $399.3KNIH RePORTER 1R43CA291415-01 · fetched Nov 12, 2026